Skip to content
DataLookout
Menu

NCT07915219

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Trial sites expanded: 383 → 394 locations
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trial
Timeframe: up to 78 weeks

Secondary (7)

Annualised rate of pulmonary exacerbations (number of events per person-time) up to Week 78
Time to first pulmonary exacerbation from first drug administration up to Week 78
Absolute change from baseline in post-bronchodilator forced expiratory volume in the first second (FEV1) %pred up to Week 78
Absolute change from baseline in post-bronchodilator forced vital capacity (FVC) %pred up to Week 78
High-resolution computed tomography (HRCT) substudy: Change from baseline (52-week HRCT from the parent trial) in total number of mucus plugs at Week 78
Show 2 moreShow less
HRCT substudy: Change from baseline (52-week HRCT from the parent trial) in volume of mucus plugs at Week 78
HRCT substudy: Change from baseline (52-week HRCT from the parent trial) in bronchial wall area over bronchial outer area (Bwa/Boa) at Week 78

Arms and interventions

Participants with bronchiectasis rolling over from parent trialsExperimental

Participants with bronchiectasis who completed parent trials AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017) and did not prematurely discontinue the trial drug.

Drugs: verducatib

Sites

394 sites in 41 countries

United States 51, China 48, Japan 35, Germany 31, Spain 21, United Kingdom 21, South Korea 16, Italy 15, Bulgaria 13, Argentina 11, France 11, Brazil 7, Latvia 7, Mexico 7, Poland 7, Portugal 7, Canada 6, Denmark 6, Israel 6, Netherlands 6, Malaysia 5, Philippines 5, Belgium 4, Finland 4, Romania 4, Singapore 4, Taiwan 4, Thailand 4, Hungary 3, Lithuania 3, Sweden 3, Austria 2, Chile 2, Czechia 2, Hong Kong 2, Ireland 2, Kazakhstan 2, Slovakia 2, Switzerland 2, Turkey (Türkiye) 2, South Africa 1